|
Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
When human SH-SY5Y neuroblastoma cells were treated with DBL or CAPE, the expression of endoplasmic reticulum (ER) stress-related genes such as HSPA5, HYOU1, DDIT3, and SEC61b increased to a larger extent in response to CAPE treatment, while that of antioxidant genes such as HMOX1, GCLM, and NQO1 increased to a larger extent in response to DBL treatment.
|
28681934 |
2018 |
|
Central neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
When human SH-SY5Y neuroblastoma cells were treated with DBL or CAPE, the expression of endoplasmic reticulum (ER) stress-related genes such as HSPA5, HYOU1, DDIT3, and SEC61b increased to a larger extent in response to CAPE treatment, while that of antioxidant genes such as HMOX1, GCLM, and NQO1 increased to a larger extent in response to DBL treatment.
|
28681934 |
2018 |
|
Childhood Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
When human SH-SY5Y neuroblastoma cells were treated with DBL or CAPE, the expression of endoplasmic reticulum (ER) stress-related genes such as HSPA5, HYOU1, DDIT3, and SEC61b increased to a larger extent in response to CAPE treatment, while that of antioxidant genes such as HMOX1, GCLM, and NQO1 increased to a larger extent in response to DBL treatment.
|
28681934 |
2018 |
|
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We used RNase protation assay and Western blot to determine levels of gamma-GCSh mRNA and protein from 10 pairs of matched carcinomas with adjacent normal controls.
|
11774239 |
2002 |
|
Steatohepatitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We recently show that systemic GSH deficiency in mice harboring a global disruption of the glutamate-cysteine ligase modifier subunit (Gclm) gene confers protection against alcohol-induced steatosis.
|
31351176 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We have shown previously that tumor cell resistance to cisplatin is associated with elevated intracellular levels of glutathione, which is accomplished at least in part by increased expression of the heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCS).
|
7671249 |
1995 |
|
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We enrolled 1977 Japanese type 2 diabetic subjects without history of CVD (males 66.1%, 59.5 ± 10.0 years old), determined their genotypes regarding glutamate-cysteine ligase modifier subunit (GCLM) C-588T, manganese superoxide dismutase (SOD2) Val16Ala, endothelial nitric oxide synthase (NOS3) G894T, NAD(P)H oxidase p22phox (CYBA) C242T, and myeloperoxidase (MPO) G-463A polymorphisms, and prospectively evaluated the association between these polymorphisms and CHD events.
|
24933031 |
2014 |
|
Malignant tumor of colon
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We designed a hammerhead ribozyme against gamma-GCS mRNA (anti-gamma-GCS Rz), which specifically down-regulated gamma-GCS gene expression in the HCT-8 human colon cancer cell line.
|
11500053 |
2001 |
|
Colon Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We designed a hammerhead ribozyme against gamma-GCS mRNA (anti-gamma-GCS Rz), which specifically down-regulated gamma-GCS gene expression in the HCT-8 human colon cancer cell line.
|
11500053 |
2001 |
|
Malignant tumor of colon
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We constructed a hammerhead ribozyme against a gamma-GCS heavy subunit (gamma-GCSh) mRNA transcript and transfected it to human colonic cancer cells (HCT8DDP) resistant to cisplatin (CDDP).
|
11687904 |
2001 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Treatment of human glioma A172 cells with 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethy-3-nitrosourea (ACNU) for 2 to 4 hr resulted in a 2- to 3-fold increase in steady-state levels of multidrug resistance-associated protein (MRP) and gamma-glutamylcysteine synthetase (gamma-GCS) mRNA.
|
9345268 |
1997 |
|
Adenoma of large intestine
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To investigate whether expression of gamma-GCS is correlated with tumor progression, we used immunohistochemical approaches to examine 16 human colorectal adenomas and resected 57 carcinomas from untreated patients.
|
11774239 |
2002 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
To investigate whether expression of gamma-GCS is correlated with tumor progression, we used immunohistochemical approaches to examine 16 human colorectal adenomas and resected 57 carcinomas from untreated patients.
|
11774239 |
2002 |
|
Skin sensitisation
|
0.010 |
Biomarker
|
disease |
BEFREE |
This assay is based on the induction of multiple marker genes (ATF3, IL-8, DNAJB4 and GCLM) related to two keratinocyte responses (inflammatory or cytoprotective) in the induction of skin sensitization.
|
27965148 |
2017 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
These results strongly suggest that MRP and gamma-GCS genes are coordinately up-regulated during colorectal carcinogenesis.
|
8705999 |
1996 |
|
Myocardial Infarction
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the -588T polymorphism of the GCLM gene may suppress GCLM gene induction in response to oxidants and that it is a genetic risk factor for MI.
|
12081989 |
2002 |
|
Myocardial Infarction
|
0.320 |
GeneticVariation
|
disease |
LHGDN |
These findings suggest that the -588T polymorphism of the GCLM gene may suppress GCLM gene induction in response to oxidants and that it is a genetic risk factor for MI.
|
12081989 |
2002 |
|
Myocardial Infarction
|
0.320 |
Biomarker
|
disease |
CTD_human |
These findings suggest that the -588T polymorphism of the GCLM gene may suppress GCLM gene induction in response to oxidants and that it is a genetic risk factor for MI.
|
12081989 |
2002 |
|
Cardiomyopathy, Familial Idiopathic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of -588T polymorphism of the GCLM gene was significantly higher in DCM patients (n = 205) than in age- and sex-matched control subjects (n = 253) (36 vs. 19%, respectively, P < 0.001).
|
23129588 |
2013 |
|
Asthma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present study was designed to investigate an association of common -588C/T and -23G/T polymorphisms within glutamate cysteine ligase modifier subunit gene with susceptibility to bronchial asthma.
|
17643973 |
2007 |
|
Myocardial Ischemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The presence of -588T allele in GCLM and -129T allele in GCLC gene genotypes was associated with an increased risk of IHD (GCLM -588T: OR = 3.92, <i>p</i> = 0.003; GCLC -129T: OR = 3.22, <i>p</i> = 0.03) for general ethnically mixed group.
|
28757675 |
2017 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer.
|
14532974 |
2003 |
|
Chronic Obstructive Airway Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The localization and expression of gamma-GCS-HS in specific lung cells as well as possible differences in its expression between smokers with and without COPD have not yet been studied.
|
10802223 |
2000 |
|
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The frequency of gamma-GCSh expression in carcinoma was significantly higher than in adenoma (p<0.0001).
|
11774239 |
2002 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression level of GCLM gene in SCLC was significantly lower than that in NSCLC (p=0.0026, Welch's t-test).
|
16012725 |
2005 |